Cargando…

Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma

Melanoma is an aggressive malignant tumor, arising more commonly on the skin, while it can also occur on mucosal surfaces and the uveal tract of the eye. In the context of the unresectable and metastatic cases that account for the vast majority of melanoma-related deaths, the currently available the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palamaris, Kostas, Moutafi, Myrto, Gakiopoulou, Hariklia, Theocharis, Stamatios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998190/ https://www.ncbi.nlm.nih.gov/pubmed/35409020 http://dx.doi.org/10.3390/ijms23073660

Ejemplares similares

Histone Deacetylases (HDACs): Promising Biomarkers and Potential Therapeutic Targets in Thymic Epithelial Tumors
por: Palamaris, Kostas, et al.
Publicado: (2023)

Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
por: Psilopatis, Iason, et al.
Publicado: (2021)

Histone Deacetylase (HDAC)-1, -2, -4, and -6 in Uveal Melanomas: Associations with Clinicopathological Parameters and Patients’ Survival
por: Levidou, Georgia, et al.
Publicado: (2021)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
por: Ghazy, Ehab, et al.
Publicado: (2022)

Histone deacetylase inhibitors: a promising partner for MEK inhibitors in uveal melanoma?
por: Faião-Flores, Fernanda, et al.
Publicado: (2019)

The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
por: Vaca, Hugo Rolando, et al.
Publicado: (2021)

Clinical Significance of Histone Deacetylase (HDAC)-1, -2, -4 and -6 Expression in Salivary Gland Tumors
por: Pouloudi, Despoina, et al.
Publicado: (2021)

Histone Deacetylases (HDAC) Inhibitor—Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor
por: Drzewiecka, Małgorzata, et al.
Publicado: (2023)

The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease
por: Bassett, Shalome A., et al.
Publicado: (2014)

Histone Deacetylase Inhibitors, Intrinsic and Extrinsic Apoptotic Pathways, and Epigenetic Alterations of Histone Deacetylases (HDACs) in Hepatocellular Carcinoma
por: Sanaei, Masumeh, et al.
Publicado: (2021)

Unraveling the Epigenetic Role and Clinical Impact of Histone Deacetylases in Neoplasia
por: Goutas, Dimitrios, et al.
Publicado: (2021)

Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors
por: Galán, María, et al.
Publicado: (2016)

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
por: Wagner, Julia M., et al.
Publicado: (2010)

Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs
por: Wang, Yuren, et al.
Publicado: (2017)

Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
por: Luo, Yuxiang, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors’ Associated Renal Toxicity: A Series of 12 Cases
por: Palamaris, Kostas, et al.
Publicado: (2022)

Optimization of Resveratrol Used as a Scaffold to Design Histone Deacetylase (HDAC-1 and HDAC-2) Inhibitors
por: Urias, Beatriz Silva, et al.
Publicado: (2022)

Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers
por: Wagner, F. F., et al.
Publicado: (2015)

Histone deacetylase (HDAC)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival
por: Giaginis, Constantinos, et al.
Publicado: (2015)

Unraveling the Immune Microenvironment of Thymic Epithelial Tumors: Implications for Autoimmunity and Treatment
por: Masaoutis, Christos, et al.
Publicado: (2022)

The Role of Peroxisome Proliferator-Activated Receptors in Polycystic Ovary Syndrome
por: Psilopatis, Iason, et al.
Publicado: (2023)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Harnessing the HDAC–histone deacetylase enzymes, inhibitors and how these can be utilised in tissue engineering
por: Lawlor, Liam, et al.
Publicado: (2019)

Hydroxyl Ketone-Based Histone Deacetylase Inhibitors To Gain Insight into Class I HDAC Selectivity versus That of HDAC6
por: Traoré, Mohamed D. M., et al.
Publicado: (2017)

Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
por: Schäker‐Hübner, Linda, et al.
Publicado: (2022)

Class I histone deacetylases (HDAC1–3) are histone lysine delactylases
por: Moreno-Yruela, Carlos, et al.
Publicado: (2022)

Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
por: Seo, Jinwon, et al.
Publicado: (2014)

Transcription Regulation by Class III Histone Deacetylases (HDACs)—Sirtuins
por: Dai, Yan, et al.
Publicado: (2008)

Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer
por: Xu, Xiaoxin S, et al.
Publicado: (2011)

Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas
por: Zhang, Qing, et al.
Publicado: (2019)

Histone Deacetylases (HDACs) and Atherosclerosis: A Mechanistic and Pharmacological Review
por: Chen, Xiaona, et al.
Publicado: (2020)

Organoids: A New Chapter in Sarcoma Diagnosis and Treatment
por: Psilopatis, Iason, et al.
Publicado: (2022)

Searching for Novel Biomarkers in Thymic Epithelial Tumors: Immunohistochemical Evaluation of Hippo Pathway Components in a Cohort of Thymic Epithelial Tumors
por: Palamaris, Kostas, et al.
Publicado: (2023)

Epigenetic modulation with oral histone deacetylase (HDAC) inhibitor as a new treatment option in JIA
por: Vojinovic, J, et al.
Publicado: (2011)

Design and in silico screening of aryl allyl mercaptan analogs as potential histone deacetylases (HDAC) inhibitors
por: Singhal, Sugandha, et al.
Publicado: (2020)

Rhein, a novel Histone Deacetylase (HDAC) inhibitor with antifibrotic potency in human myocardial fibrosis
por: Barbosa, David Monteiro, et al.
Publicado: (2020)

Comprehensive Mechanistic View of the Hydrolysis of Oxadiazole-Based Inhibitors by Histone Deacetylase 6 (HDAC6)
por: Motlová, Lucia, et al.
Publicado: (2023)

Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma
por: Yeon, Minjeong, et al.
Publicado: (2020)

CD4(+) T cell lineage integrity is controlled by the histone deacetylases HDAC1 and HDAC2
por: Boucheron, Nicole, et al.
Publicado: (2014)

Immunohistochemical Study of Bladder Cancer Molecular Subtypes and Their Association with PD-L1 Expression
por: Goutas, Dimitrios, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7t0nrpademhnk9oc62b84nfra6